The Manufacturers Life Insurance Company Raises Stock Holdings in Billiontoone, Inc. $BLLN

The Manufacturers Life Insurance Company boosted its stake in Billiontoone, Inc. (NASDAQ:BLLN) by 151.8% in the first quarter, HoldingsChannel reports. The firm owned 30,506 shares of the company’s stock after acquiring an additional 18,389 shares during the period. The Manufacturers Life Insurance Company’s holdings in Billiontoone were worth $2,408,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA purchased a new position in Billiontoone in the fourth quarter worth about $13,373,000. Baillie Gifford & Co. purchased a new stake in shares of Billiontoone during the 4th quarter valued at about $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Billiontoone during the 4th quarter valued at about $1,348,000. UBS Group AG bought a new position in shares of Billiontoone in the 4th quarter worth approximately $2,586,000. Finally, Renaissance Capital LLC purchased a new position in shares of Billiontoone in the fourth quarter worth approximately $201,000.

Analyst Ratings Changes

BLLN has been the subject of a number of research reports. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. BTIG Research lowered their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. reduced their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Guggenheim began coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target on the stock. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Price Performance

BLLN stock opened at $93.39 on Friday. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44. The company has a quick ratio of 10.58, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $116.49 and a two-hundred day simple moving average of $94.28. The firm has a market capitalization of $4.30 billion and a P/E ratio of 133.41.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. Analysts anticipate that Billiontoone, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Bosch John Roderick Ten sold 1,416 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00. Following the sale, the senior vice president owned 33,552 shares in the company, valued at approximately $4,026,240. This represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nancy Joann Johnson sold 801 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $124.91, for a total value of $100,052.91. Following the completion of the sale, the insider owned 21,099 shares of the company’s stock, valued at approximately $2,635,476.09. This represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 202,049 shares of company stock valued at $23,496,861. Insiders own 50.22% of the company’s stock.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.